1 minute read
Dec. 20, 2021
PF-07321332: an Oral, Reversible Covalent SARS-CoV-2 Main Protease Inhibitor
paxlovid
oral pan-coronavirus antiviral, rev. covalent Ph. III candidate for COVID-19 (300 mg BID) from SARS-CoV-1 inhibitor (WO2005113580) Science Pfizer Worldwide Research
Reviewer:
Loading...
